HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

BACKGROUND: Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially improve outcomes for patients with ovarian...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuefferd, Marianne, Couturier, Jérôme, Penault-Llorca, Frédérique, Vincent-Salomon, Anne, Broët, Philippe, Guastalla, Jean-Paul, Allouache, Djelila, Combe, Martin, Weber, Béatrice, Pujade-Lauraine, Eric, Camilleri-Broët, Sophie
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042515/
https://www.ncbi.nlm.nih.gov/pubmed/17987122
http://dx.doi.org/10.1371/journal.pone.0001138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042515/
https://www.ncbi.nlm.nih.gov/pubmed/17987122
http://dx.doi.org/10.1371/journal.pone.0001138

Ejemplares similares